Atria Investments Inc Buys Shares of 10,009 Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Atria Investments Inc bought a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,009 shares of the company’s stock, valued at approximately $112,000.

Other hedge funds have also added to or reduced their stakes in the company. Summit Securities Group LLC purchased a new position in Pliant Therapeutics during the 2nd quarter valued at about $59,000. SG Americas Securities LLC purchased a new position in Pliant Therapeutics during the 1st quarter valued at about $107,000. Deerfield Management Company L.P. Series C purchased a new position in Pliant Therapeutics during the 2nd quarter valued at about $126,000. China Universal Asset Management Co. Ltd. grew its holdings in Pliant Therapeutics by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after buying an additional 4,607 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in Pliant Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 14,489 shares of the company’s stock valued at $216,000 after buying an additional 1,203 shares in the last quarter. Hedge funds and other institutional investors own 97.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Pliant Therapeutics in a report on Thursday, August 8th. Leerink Partners assumed coverage on Pliant Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $33.00 price objective for the company. Oppenheimer cut their price objective on Pliant Therapeutics from $48.00 to $45.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Leerink Partnrs raised Pliant Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 price objective on shares of Pliant Therapeutics in a report on Thursday, August 8th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $40.57.

Pliant Therapeutics Stock Up 1.0 %

PLRX opened at $12.98 on Monday. The stock has a market capitalization of $789.88 million, a price-to-earnings ratio of -3.89 and a beta of 1.08. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. Pliant Therapeutics, Inc. has a twelve month low of $10.22 and a twelve month high of $19.62. The firm has a 50 day moving average price of $13.11 and a 200-day moving average price of $12.75.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.